- June 8, 2017
- Posted by:
- Category: FundingSMEs.com
Deciphera Pharmaceuticals has raised $52 million in Series C funding.
Founded in 2003, Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies.
The proceeds will enable Deciphera to advance its pipeline of novel oncology products into later-stage clinical development.
|Founder / CEO||Michael D. Taylor|
|Sphera Global Healthcare Fund|
|Viking Global Investors|
|Previous Investors||SV Health Investors|
|New Leaf Venture Partners|